Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Dixie Regional Medical Center - East Campus
mi
from
Saint George, UT
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Dixie Regional Medical Center - East Campus
mi
from
Saint George, UT
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
LDS Hospital
mi
from
Salt Lake City, UT
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
LDS Hospital
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Norris Cotton Cancer Center-North
mi
from
Saint Johnsbury, VT
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Norris Cotton Cancer Center-North
mi
from
Saint Johnsbury, VT
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Sentara Cancer Institute at Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Sentara Cancer Institute at Sentara Norfolk General Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Naval Medical Center - Portsmouth
mi
from
Portsmouth, VA
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Naval Medical Center - Portsmouth
mi
from
Portsmouth, VA
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
North Star Lodge
mi
from
Yakima, WA
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
North Star Lodge
mi
from
Yakima, WA
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Theda Care Cancer Institute
mi
from
Appleton, WI
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Theda Care Cancer Institute
mi
from
Appleton, WI
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
St. Vincent Hospital Regional Cancer Center
mi
from
Green Bay, WI
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Bay Area Cancer Care Center at Bay Area Medical Center
mi
from
Marinette, WI
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Community Memorial Hospital Cancer Care Center
mi
from
Menomonee Falls, WI
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Community Memorial Hospital Cancer Care Center
mi
from
Menomonee Falls, WI
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Medical College of Wisconsin Cancer Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
Veterans Affairs Medical Center - Milwaukee
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
West Allis Memorial Hospital
mi
from
West Allis, WI
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
West Allis Memorial Hospital
mi
from
West Allis, WI
Click here to add this to my saved trials
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated:  10/23/2017
British Columbia Cancer Agency - Vancouver Island Centre
mi
from
Victoria,
Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy
A Phase III Randomized Study to Evaluate the Efficacy of Zometa® for the Prevention of Osteoporosis and Associated Fractures in Patients Receiving Radiation Therapy and Long Term LHRH Agonists for High-Grade and/or Locally Advanced Prostate Cancer
Status: Enrolling
Updated: 10/23/2017
British Columbia Cancer Agency - Vancouver Island Centre
mi
from
Victoria,
Click here to add this to my saved trials
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination With Radiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II, Multi-Center Trial
Status: Enrolling
Updated:  10/23/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Concurrent Carboplatin, Paclitaxel and Selenomethionine in Combination With Radiation for Patients With Unresectable Stage III Non-Small Cell Lung Cancer: A Phase II, Multi-Center Trial
Status: Enrolling
Updated: 10/23/2017
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
1160.189.10250 Boehringer Ingelheim Investigational Site
mi
from
Beverly Hills, CA
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
1160.189.10250 Boehringer Ingelheim Investigational Site
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Orlando, FL
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Chicago, IL
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
1218.22.4161 Boehringer Ingelheim Investigational Site
mi
from
Joliet, IL
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
1218.22.4161 Boehringer Ingelheim Investigational Site
mi
from
Joliet, IL
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
1200.32.2606 Boehringer Ingelheim Investigational Site
mi
from
Metairie, LA
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
1200.32.2606 Boehringer Ingelheim Investigational Site
mi
from
Metairie, LA
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Baltimore, MD
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Baltimore, MD
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
1218.61.01052 Boehringer Ingelheim Investigational Site
mi
from
Las Vegas, NV
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
1218.61.01052 Boehringer Ingelheim Investigational Site
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
205.440.1011 Boehringer Ingelheim Investigational Site
mi
from
Lebanon, NH
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
205.440.1011 Boehringer Ingelheim Investigational Site
mi
from
Lebanon, NH
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Charlotte, NC
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
Boehringer Ingelheim Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
1160.129.32095 Boehringer Ingelheim Investigational Site
mi
from
Beaumont, TX
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
1160.129.32095 Boehringer Ingelheim Investigational Site
mi
from
Beaumont, TX
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
1218.61.01041 Boehringer Ingelheim Investigational Site
mi
from
Tyler, TX
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
1218.61.01041 Boehringer Ingelheim Investigational Site
mi
from
Tyler, TX
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
1301.1.5799 Boehringer Ingelheim Investigational Site
mi
from
Webster, TX
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
1301.1.5799 Boehringer Ingelheim Investigational Site
mi
from
Webster, TX
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
1220.48.0042 Boehringer Ingelheim Investigational Site
mi
from
Fairfax, VA
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
1220.48.0042 Boehringer Ingelheim Investigational Site
mi
from
Fairfax, VA
Click here to add this to my saved trials
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated:  10/23/2017
1230.2.51 Boehringer Ingelheim Investigational Site
mi
from
Tainan,
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy
Status: Enrolling
Updated: 10/23/2017
1230.2.51 Boehringer Ingelheim Investigational Site
mi
from
Tainan,
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
University of Chicago
mi
from
Chicago, IL
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Dana Farber Cancer Center Institute
mi
from
Boston, MA
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Dana Farber Cancer Center Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
University of Alabama at Birmingham (UAB)
mi
from
Birmingham, AL
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Vanderbilt University
mi
from
Nashville, TN
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Baylor University
mi
from
Houston, TX
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Baylor University
mi
from
Houston, TX
Click here to add this to my saved trials
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated:  10/24/2017
Georgetown University Medical Center
mi
from
Washington, D.C.,
Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
An Open Label, Randomized, Phase II Trial of Abraxane (Paclitaxel Albumin-Bound Particles for Injectable Suspension), With or Without Tigatuzumab (a Humanized Monoclonal Antibody Targeting Death Receptor 5) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer
Status: Enrolling
Updated: 10/24/2017
Georgetown University Medical Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Mitochondrial Respiratory Function in Mammalian Skeletal Muscle
Mitochondrial Respiratory Function in Mammalian Skeletal Muscle: Metabolic Insights Into Cancer and Burn Cachexia Through Comparative Physiology of Humans and Marine Mammals
Status: Enrolling
Updated:  10/24/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Mitochondrial Respiratory Function in Mammalian Skeletal Muscle
Mitochondrial Respiratory Function in Mammalian Skeletal Muscle: Metabolic Insights Into Cancer and Burn Cachexia Through Comparative Physiology of Humans and Marine Mammals
Status: Enrolling
Updated: 10/24/2017
University of Texas Medical Branch
mi
from
Galveston, TX
Click here to add this to my saved trials
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Status: Enrolling
Updated:  10/24/2017
Kaiser Foundation Research Institute
mi
from
Oakland, CA
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Status: Enrolling
Updated: 10/24/2017
Kaiser Foundation Research Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Status: Enrolling
Updated:  10/24/2017
University of Colorado Denver
mi
from
Aurora, CO
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Sun Safe Workplaces: Assessment of Benefits and Costs of a Policy Intervention
Status: Enrolling
Updated: 10/24/2017
University of Colorado Denver
mi
from
Aurora, CO
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
A Multi-Center Phase II Study of the Halichondrin B Analog E7389 in Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Status: Enrolling
Updated:  10/24/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
A Multi-Center Phase II Study of the Halichondrin B Analog E7389 in Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Status: Enrolling
Updated: 10/24/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
A Multi-Center Phase II Study of the Halichondrin B Analog E7389 in Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Status: Enrolling
Updated:  10/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Eribulin Mesylate in Treating Patients With Recurrent Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer
A Multi-Center Phase II Study of the Halichondrin B Analog E7389 in Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
Status: Enrolling
Updated: 10/24/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Limonene Study in Women With Breast Cancer
Clinical Study of Limonene in Women With a Recent Diagnosis of Early Stage Breast Cancer Electing to Undergo Excision Surgery
Status: Enrolling
Updated:  10/25/2017
Arizona Cancer Center
mi
from
Tucson, AZ
Limonene Study in Women With Breast Cancer
Clinical Study of Limonene in Women With a Recent Diagnosis of Early Stage Breast Cancer Electing to Undergo Excision Surgery
Status: Enrolling
Updated: 10/25/2017
Arizona Cancer Center
mi
from
Tucson, AZ
Click here to add this to my saved trials